Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)
Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS
The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.
This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).
This study plans to include individuals with RLS, who will be divided into two groups:
- One group will receive intravenous iron immediately after the baseline polysomnography
- The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yves DAUVILLIERS, MD - PhD
- Phone Number: 0033 467 3374 78
- Email: y-dauvilliers@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France
- CHU de Montpellier
-
Contact:
- Yves DAUVILLIERS, MD PhD
- Phone Number: 033 4 6733 7478
- Email: y-dauvilliers@chu-montpellier.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years;
- Weight ≥ 50 kg;
- Drug-resistant RLS;
- Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
- Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
- Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
- In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
- Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.
Exclusion Criteria:
- Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
- Serum ferritin < 50 µg/L or > 300 µg/L;
- Transferrin saturation < 20% or > 45%;
- Hemochromatosis;
- RLS augmentation syndrome ;
- Treatment with neuroleptics or antidepressants;
- Allergy to iron;
- Severe infectious or inflammatory disease within the past 3 months;
- RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
- Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
- Known allergy, inflammatory, or immune disorder;
- History of severe asthma, eczema, or any other atopic allergy;
- Pregnancy or breastfeeding;
- Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
|
Active Comparator: Delayed-onset treatment
The treatment will be administered at 12 weeks
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IRLSSG-Q score
Time Frame: From Day 0 to Week 12
|
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
|
From Day 0 to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Periodic Limb Movements during Sleep (PLMS) index
Time Frame: From V1 (Day 0) to V5 (week 24)
|
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography.
15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
|
From V1 (Day 0) to V5 (week 24)
|
|
Total sleep time
Time Frame: From day 0 to week 24
|
Total sleep time measured in minutes during polysomnography.
|
From day 0 to week 24
|
|
Sleep latency
Time Frame: From Day 0 to week 24
|
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
|
From Day 0 to week 24
|
|
Sleep time at stage 1-2 during polysomnography
Time Frame: From Day 0 to week 24
|
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Sleep time at stage 3 during polysomnography
Time Frame: From Day 0 to week 24
|
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Micro-awakenings index (MAI)
Time Frame: From Day 0 to week 24
|
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
|
From Day 0 to week 24
|
|
Apnea-hypopnea index (AHI)
Time Frame: From Day 0 to week 24
|
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
|
From Day 0 to week 24
|
|
Average arterial oxygen saturation (SaO2)
Time Frame: From Day 0 to Week 24
|
The unit of measurement for SaO2 is the percentage (%).
|
From Day 0 to Week 24
|
|
Oxygen desaturation index (IDO)
Time Frame: From Day 0 to week 24
|
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
|
From Day 0 to week 24
|
|
Serum ferritin
Time Frame: From Day 0 to week 24
|
From Day 0 to week 24
|
|
|
Transferrin saturation coefficient
Time Frame: From Day 0 to Week 24
|
From Day 0 to Week 24
|
|
|
Epworth Sleepiness Scale (ESS)
Time Frame: From Day 0 to Week 24
|
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day.
Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place).
Each situation is scored from 0 to 3 based on the likelihood of falling asleep.
Total score 0-24; a score of ≥10 suggests excessive sleepiness
|
From Day 0 to Week 24
|
|
European Quality of Life 5 Dimensions (EQ-5D)
Time Frame: From Day 0 to Week 24
|
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
|
From Day 0 to Week 24
|
|
Clinical Global Impression (CGI)
Time Frame: From Day 0 to Week 24
|
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change).
7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
|
From Day 0 to Week 24
|
|
Patient Global Impression (PGI)
Time Frame: From Day 0 to Week 24
|
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported.
A high score is associated with patients perceiving their symptoms as severe
|
From Day 0 to Week 24
|
|
Beck Depression Inventory-II (BDI-II)
Time Frame: From Day 0 to Week 24
|
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
|
From Day 0 to Week 24
|
|
Augmentation Severity Rating Scale (ASRS)
Time Frame: From Day 0 to Week 24
|
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists.
It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
|
From Day 0 to Week 24
|
|
Insomnia Severity Index (ISI)
Time Frame: From Day 0 to week 24
|
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood).
A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
|
From Day 0 to week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Mental Disorders
- Sleep Wake Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Parasomnias
- Restless Legs Syndrome
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Research Design
- Epidemiologic Methods
- Research Design
- Methods
- Therapeutics
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Biopsy
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Behavior Control
- Immobilization
- Diagnostic Techniques, Neurological
- Surveys and Questionnaires
- Restraint, Physical
- Spinal Puncture
- Random Allocation
- ferric carboxymaltose
Other Study ID Numbers
Other Study ID Numbers
- RECHMPL25_0557
- 2026-525613-31-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.